TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.
about
TAT‑fused IP3R‑derived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@en
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@nl
type
label
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@en
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@nl
prefLabel
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@en
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@nl
P2093
P2860
P356
P1476
TAT‑fused IP3R‑derived peptide ...... by increasing ER Ca2+ release.
@en
P2093
Liankun Sun
Minghan Dou
Weinan Gao
Yong Zhang
Yuting Guo
P2860
P304
P356
10.3892/IJMM.2017.3260
P50
P577
2017-11-16T00:00:00Z